Abivax reports H1 2026 results, says NDA filing for obefazimod still on track for Q4Sep 21Quarterly updateAbivax S.A.obefazimod
Abivax posts Phase 3 results for obefazimod in ulcerative colitis across ABTECT-1 and ABTECT-2Sep 10Weekly roundup, 2 itemsAbivax S.A.obefazimod
Abivax prices $800 million ADS offering, cites Phase 3 UC maintenance dataJul 2FinancingAbivax S.A.obefazimod
Abivax reports Part 2 maintenance data for obefazimod in ulcerative colitisJun 29Clinical readoutAbivax S.A.obefazimod
Sign inSign in